Name

Insera Therapeutics

Legal name

Insera Therapeutics, LLC

Website

https://inseratherapeutics.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Neurovascular Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

Keywords

• Neurovascular medical devices
• Stroke treatment devices
• Cerebral aneurysm devices
• Minimally invasive therapeutics
• Endovascular medical devices

Headquarters

HQ city

Sacramento

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others

Revenue model

1. Medical device sales (future commercialization): Insera Therapeutics is a medical device company developing innovative neurovascular products. As of the available source material, the company describes itself in product-development mode ("developing innovative products"), with a stated ambition to deliver products and services to patients worldwide. Commercial revenue model is therefore expected to be one-time/recurring hardware sales of FDA-cleared/approved medical devices to hospitals and clinical sites, though no explicit pricing, launch, or sales figures are disclosed in the source material.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Insera Therapeutics develops minimally invasive medical devices for the treatment of neurovascular diseases, with a focused portfolio spanning acute stroke treatment devices and cerebral aneurysm treatment devices. The company is positioned as a product-development-stage medical device maker targeting two of the highest-burden neurovascular conditions globally.

Product overview

Insera Therapeutics, LLC is a Sacramento, CA-based medical devices company offering a focused portfolio of minimally invasive therapeutics for neurovascular diseases. Its products are organized around two core clinical focus areas — Acute Stroke Treatment Devices and Cerebral Aneurysm Treatment Devices — which together support the company's mission to be the most competitive and innovative provider of cures for neurovascular diseases through relentless, patient-focused innovation.

Differentiator

Problem solved

Functional benefit

Products and services

• Acute Stroke Treatment Devices
• Cerebral Aneurysm Treatment Devices Minimally invasive medical devices developed by Insera Therapeutics for the treatment of cerebral aneurysms, complementing the company's neurovascular disease portfolio alongside its acute stroke treatment offerings. Target users are hospitals, neurosurgeons, and interventional neuroradiologists treating cerebral aneurysm patients.

Quantifiable outcome

• Targets a US stroke patient population of over 700,000 per year
• +1 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Turbify (Yahoo!)minorOthersInsera Therapeutics' corporate website is hosted by Turbify (a Yahoo! small-business hosting service). This is an operational website-hosting relationship, not a strategic commercial, technology, or financial partnership. Source: "Hosted by Yahoo! (Turbify)" footer on the homepage.

Scale indicators4 records

Recent moves2 records

Expansion highlights3 records

Emerging players

• MIVI Neuroscience: MIVI Neuroscience develops the Q Aspiration Catheter and other devices for ischemic and hemorrhagic stroke treatment. It is a relevant emerging peer targeting the same neurovascular hospital customer as Insera.
• Imperative Care: Imperative Care is a venture-backed neurovascular company developing the Zoom aspiration catheter system and stroke thrombectomy devices. As an emerging challenger, it is highly comparable to where Insera aims to be — a focused neurovascular platform targeting the same hospital call point with next-generation devices.
• Rapid Medical: Rapid Medical is an Israeli neurovascular device company developing Tigertriever (adjustable stroke thrombectomy device) and other minimally invasive aneurysm/stroke products. Its minimally invasive philosophy and indication overlap make it a relevant emerging peer to Insera.
• Route 92 Medical: Route 92 Medical is a privately held neurovascular company developing the FreeClimb and SuperBore catheter systems for mechanical thrombectomy. It is comparable as a venture-backed neurovascular startup focused on acute ischemic stroke intervention.
• InNeuroCo: InNeuroCo is an early-stage neurovascular device company developing access and support catheters for stroke intervention. Its narrow focus and emerging status parallel Insera's profile and target the same interventional neuroradiology buyer.
• Artio Medical: Artio Medical is a private medical device developer focused on neurovascular and cardiovascular solutions, including flow diversion and aneurysm products. Its minimally invasive neurovascular portfolio and pre-commercial stage make it a useful emerging peer comparable to Insera.

Direct peers

• Penumbra, Inc. Penumbra is a pure-play neurovascular and peripheral vascular device company best known for its mechanical thrombectomy systems (Penumbra System, Indigo) and stroke aspiration catheters. It is the closest direct peer to Insera's acute stroke and aneurysm focus, with an endovascular, minimally invasive portfolio sold to the same interventional neuroradiology call point.

Broad incumbents

• Stryker (Neurovascular): Stryker's Neurovascular division (built around the Target/Covidian acquisition) offers coils, stents, flow diverters, and Trevo thrombectomy devices for ischemic and hemorrhagic stroke. It is a broad incumbent in Insera's exact clinical indications, with global hospital sales coverage Insera would have to match.
• Medtronic (Neurovascular): Medtronic's Neurovascular business (acquired via Covidien) includes the Solitaire and React thrombectomy platforms and a full portfolio of coils and access devices. It competes head-to-head with Insera in acute ischemic stroke and aneurysm treatment through the same hospital channel.
• Johnson & Johnson (Cerenovus): Cerenovus is J&J's neurovascular franchise, offering embolic coils, flow diverters (Pipeline), and revascularization devices. It is a broad incumbent directly overlapping Insera's stroke and aneurysm indications, with significant clinical evidence and KOL relationships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/insera-therapeutics-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Insera Therapeutics